Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Non-Current Assets (2020 - 2025)

Maxcyte (MXCT) has disclosed Non-Current Assets for 6 consecutive years, with $88.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets rose 17.34% to $88.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $307.4 million, a 0.49% change, with the full-year FY2024 number at $67.8 million, down 13.18% from a year prior.
  • Non-Current Assets was $88.8 million for Q3 2025 at Maxcyte, up from $76.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $88.8 million in Q3 2025 to a low of $8.2 million in Q3 2021.
  • A 5-year average of $49.7 million and a median of $43.7 million in 2023 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: soared 318.61% in 2022, then decreased 13.18% in 2024.
  • Maxcyte's Non-Current Assets stood at $13.7 million in 2021, then soared by 151.23% to $34.4 million in 2022, then soared by 127.06% to $78.1 million in 2023, then decreased by 13.18% to $67.8 million in 2024, then soared by 31.05% to $88.8 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Non-Current Assets are $88.8 million (Q3 2025), $76.5 million (Q2 2025), and $74.2 million (Q1 2025).